文献速递临床试验与 GCP

评估新批准药物联合方案治疗氟喹诺酮类耐药的多药耐药结核病(endTB-Q):多国随机对照试验研究方案

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
PubMed 文献 · Trials · 2023-11-30

endTB-Q是一项III期、多国、随机、对照、平行、开放标签临床试验,评估含贝达喹啉、利奈唑胺、氯法齐明和德拉马尼的缩短全口服方案治疗氟喹诺酮类耐药的多药耐药/利福平耐药结核病(pre-XDR TB)的疗效与安全性。参与者按2:1随机分配至实验组或对照组,实验组疗程根据基线痰涂片镜检和胸部影像学及6个月时痰培养结果决定为6或9个月,对照组为同期WHO标准治疗。主要目的是评估实验方案73周时疗效是否非劣于对照,样本量324例,非劣效界值12%,单侧α=0.025,把握度至少80%。

要点

  • endTB-Q为III期多国随机对照试验,纳入氟喹诺酮类耐药的MDR/RR-TB患者,随机2:1分配至实验组或对照组。
  • 实验组为贝达喹啉、利奈唑胺、氯法齐明和德拉马尼全口服联合方案,疗程6或9个月由基线病变程度和6个月痰培养结果决定。
  • 主要目的为评估实验方案73周时疗效非劣于对照,非劣效界值12%,样本量324例,把握度至少80%。

核心结论

  • 这项针对pre-XDR TB缩短治疗的内对照研究,将为四药全口服缩短方案的临床和政策决策提供急需的数据和证据。

研究设计与样本

  • endTB-Q为III期、多国、随机、对照、平行、开放标签临床试验,评估pre-XDR TB治疗策略的疗效和安全性。
  • 参与者按2:1随机分配至实验组或对照组,随机化按国家和根据筛查/基线特征定义的结核病病变程度表型分层。
  • 研究参与持续至随机化后最长104周,样本量324例(两臂合计),主要目标为评估实验方案73周时疗效是否非劣于对照。

主要发现

  • 实验组包含贝达喹啉、利奈唑胺、氯法齐明和德拉马尼;对照组为同期WHO针对pre-XDR TB的标准治疗。
  • 实验组疗程由基线和6个月时痰涂片镜检、胸部影像学及痰培养结果综合决定:病变范围较小的参与者接受6个月治疗,病变范围较大的接受9个月治疗。
  • 样本量324例可提供至少80%把握度,在改良意向治疗和符合方案人群中以单侧α=0.025、非劣效界值12%显示非劣效性。

关键数值与推荐

  • 非劣效界值为12%,单侧α=0.025,把握度至少80%,样本量324例,主要评估时间点为73周。
  • 实验组疗程:病变范围较小者6个月,病变范围较大者9个月;研究参与持续至随机化后最长104周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens. To date, there has been no randomized, internally and concurrently controlled trial of a shorter, all-oral regimen comprising these newer and repurposed drugs sufficiently powered to produce results for pre-XDR TB patients. METHODS: endTB-Q is a phase III, multi-country, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of a treatment strategy for patients with pre-XDR TB. Study participants are randomized 2:1 to experimental or control arms, respectively. The experimental arm contains bedaquiline, linezolid, clofazimine, and delamanid. The control comprises the contemporaneous WHO standard of care for pre-XDR TB. Experimental arm duration is determined by a composite of smear microscopy and chest radiographic imaging at baseline and re-evaluated at 6 months using sputum culture results: participants with less extensive disease receive 6 months and participants with more extensive disease receive 9 months of treatment. Randomization is stratified by country and by participant extent-of-TB-disease phenotype defined according to screening/baseline characteristics. Study participation lasts up to 104 weeks post randomization. The primary objective is to assess whether the efficacy of experimental regimens at 73 weeks is non-inferior to that of the control. A sample size of 324 participants across 2 arms affords at least 80% power to show the non-inferiority, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per-protocol populations. DISCUSSION: This internally controlled study of shortened treatment for pre-XDR TB will provide urgently needed data and evidence for clinical and policy decision-making around the treatment of pre-XDR TB with a four-drug, all-oral, shortened regimen. TRIAL REGISTRATION: ClinicalTrials.Gov NCT03896685. Registered on 1 April 2018; the record was last updated for study protocol version 4.3 on 17 March 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Patil SB, Tamirat M, Khazhidinov K, et al. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023. PMID: 38037119. doi:10.1186/s13063-023-07701-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。